Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation

American Journal of Hematology

Volumn 83, Issue 10, 2008, Pages 825-827

  Ustun, Celalettin ^a   Kalla, Abhishek ^a   Farrow, Stephanie ^a   DeRemer, David L ^a   Jlllella, Anand ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CYTOGENETICS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; HLA MATCHING; HUMAN; KARYOTYPING; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAINTENANCE THERAPY; MATCHED UNRELATED DONOR TRANSPLANTATION; MEAN CORPUSCULAR VOLUME; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELOBLAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MIDDLE AGED; RECURRENCE; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 53549124697     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21267     Document Type: Letter

References (14)

1. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803.
2. Silva LD dM, Kantarjian H, Champlin R, et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2′-deoxy-5 azacytidine for patients with myelodysplastic syndrome. Blood 2007;110:1468a.
3. Lubbert MRB, Schmid M, Knipp S, et al. Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: First results of a multicenter Phase II study. Blood 2005;106:1852a.
4. Ravandi FIJ, Faderl S, Garcia-Manero G, et al. Randomized study of decitabine versus observation or continued cytotoxic chemotherapy in patients with intermediate and poor risk acute myeloid leukemia in first or subsequent complete remission. Blood 2007;110:2859a.
5. Graef T, Kuendgen A, Fenk R, et al. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007;31:257-259.
6. Rossetti JM, Shadduck RK, Chandana Thatikonda C, et al. Low-dose azacitidine for relapse of MDS/AML after unrelated donor peripheral blood stem cell transplantation. Blood 2007;110:5034a.
7. Cashen AF, Devine H, DiPersio J. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine. Am J Hematol 2006;81:543-545.
8. Estey E, Treatment of refractory AML. Leukemia 1996;10:932-936.
9. Lee S, Tallman MS, Oken MM, et al. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group. Leukemia 2000;14:1345-1348.
10. Levy V, Marjanovic Z, Vekhoff A, et al. Relapse after autologous hematopoietic stem cell transplantation in acute myeloid leukemia, a single center experience over 13 years. Am J Hematol 2000;64:232-233.
11. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969-1978.
12. Breems DA, Boogaerts MA, Dekker AW, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 2005;128:59-65.
13. Bug G, Atta J, Klein SA, et al. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol 2005;84:748-754.
14. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550-1558.